PD-1 and PD-L1 Inhibitors Market Size, Share & Trends Analysis Report By Drug Type (Atezolizumab, Avelumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab, Sintilimab, and Others), By Disease Type, Region And Segment Forecasts, 2025-2034

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global PD-1 and PD-L1 Inhibitors Market Snapshot Chapter 4. Global PD-1 and PD-L1 Inhibitors Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Penetration & Growth Prospect Mapping 4.6. Clinical Trial/Pipeline Analysis 4.7. Industry Analysis – Porter's Five Forces Analysis 4.8. Competitive Landscape & Market Share Analysis 4.9. Key Trends in the Market Chapter 5. Market Segmentation 1: Drugs Estimates & Trend Analysis 5.1. Drugs Type & Market Share, 2024 & 2034 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drugs: 5.2.1. Pembrolizumab 5.2.2. Nivolumab 5.2.3. Atezolizumab 5.2.4. Durvalumab 5.2.5. Avelumab 5.2.6. Cemiplimab 5.2.7. Sintilimab 5.2.8. Others Chapter 6. PD-1 and PD-L1 Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis 6.1. Indication Analysis & Market Share, 2024 & 2034 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication: 6.2.1. Melanoma 6.2.2. NSCLC 6.2.3. Renal cell carcinoma 6.2.4. Urothelial bladder cancer 6.2.5. Hodgkins Lymphoma 6.2.6. Merkel cell carcinoma 6.2.7. Colorectal cancer 6.2.8. Others Chapter 7. PD-1 and PD-L1 Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. North America 7.1.1. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Drugs, 2021-2034 7.1.2. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Indication, 2021-2034 7.1.3. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Country, 2021-2034 7.1.3.1. U.S. 7.1.3.2. Canada 7.2. Europe 7.2.1. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034 7.2.2. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034 7.2.3. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034 7.2.3.1. Germany 7.2.3.2. Poland 7.2.3.3. France 7.2.3.4. Italy 7.2.3.5. Spain 7.2.3.6. UK 7.2.3.7. Rest of Europe 7.3. Asia Pacific 7.3.1. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034 7.3.2. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034 7.3.3. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034 7.3.3.1. China 7.3.3.2. India 7.3.3.3. Japan 7.3.3.4. Australia 7.3.3.5. Rest of Asia Pacific 7.4. Latin America 7.4.1. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034 7.4.2. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034 7.4.3. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034 7.4.3.1. Brazil 7.4.3.2. Rest of Latin America 7.5. MEA 7.5.1. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drug, 2021-2034 7.5.2. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by country, 2021-2034 7.5.2.1. South Africa 7.5.2.2. Rest of MEA Chapter 8. Competitive Landscape 8.1. Major M &A /Research Institutes Partnerships, Alliances, and Agreements 8.2. Funding Activities 8.3. Company Profiles 8.3.1. Merck Co. 8.3.2. Bristol-Myers Squibb 8.3.3. Roche 8.3.4. AstraZeneca 8.3.5. Pfizer 8.3.6. Jiangsu HengRui Medicine 8.3.7. Regeneron Pharmaceuticals 8.3.8. ONO PHARMACEUTICAL CO., LTD. 8.3.9. Eli Lilly and Company 8.3.10. Innovent Biologics, Inc. 8.3.11. BeiGene 8.3.12. Junshi Biosciences Co. 8.3.13. Biocad 8.3.14. 4D pharma plc. 8.3.15. Agenus Inc. 8.3.16. Calithera. 8.3.17. Curis, Inc. 8.3.18. Constellation Pharmaceuticals, Inc. 8.3.19. Compass Therapeutics 8.3.20. Corvus Pharmaceuticals 8.3.21. CytomX Therapeutics, Inc. 8.3.22. eFFECTOR Therapeutics, Inc. 8.3.23. Jounce Therapeutics, Inc. 8.3.24. MacroGenics, Inc. 8.3.25. Mirati Therapeutics, Inc. 8.3.26. Moderna, Inc. 8.3.27. MultiVir, Inc. 8.3.28. NovoCure Ltd. 8.3.29. NeoImmuneTech, Inc. 8.3.30. Syndax Pharmaceuticals 8.3.31. PrimeVax Immuno-Oncology Inc. 8.3.32. Incyte Corporation 8.3.33. Trillium Therapeutics Inc.